Oral presentation of preclinical and preliminary toxicology data on its BET BD1 program at Discovery on Target 2016

Stockholm, 22 September 2016. Nuevolution AB (publ) (NUE.ST) will today present
preclinical and preliminary toxicology data from its BET BD1 program at
Discovery on Target 2016 (DoT 2016) in Boston, MA, USA.

Jimmi G. Seitzberg, Project Manager, Nuevolution, will give an oral presentation
reporting the key findings from the poster “NUE7770 - A BET-BD1 selective
chemical probe with potent cellular and in vivo anti-inflammatory activity”,
also including preliminary data from the first comparative animal toxicology
study with NUE7770, selective BET BD1 inhibitor.

The preliminary data from a two-week mouse toxicology study with Nuevolution’s
selective BET inhibitor NUE7770 showed no mortality and no loss in body weight
even at high doses of the compound, whereas the non-selective BET control
compound, JQ1, showed a high mortality already at lower doses.

The final conclusion from this toxicology study is not yet available as further
studies still are ongoing. A full characterisation and conclusion from this
comparative animal toxicology study will be available in the fourth quarter
2016.

NUE7770 is also being tested in mouse models of Systemic Lupus Erythematosus
(SLE) and Idiopathic Lung Fibrosis (IPF), severe inflammatory diseases. Data
from these studies will be reported later in 2016.

For more information, please contact:

Thomas Franch, CSO

Phone: +45 7020 0987

Email: tf@nuevolution.com

Henrik D. Simonsen, CFO

Phone: +45 3913 0947

Email: hs@nuevolution.com

About bromodomain proteins

BET bromodomain proteins play an important role in regulation of gene
expression, which thereby affect inflammatory responses and the ability of
cancer cells to sustain growth and survive. The human proteome comprises 46
bromodomain-containing proteins, many of which are thought to be involved in
cancer, inflammation and cardiovascular disease.

About Nuevolution

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company
founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its
proprietary discovery platform and programs with pharmaceutical and
biotechnology companies to seek future benefit of patients in need of novel
medical treatment options. Nuevolution’s internal programs are focused
on therapeutically important targets within inflammation, oncology and immuno
-oncology.

Nuevolution AB (publ) is required to disclose the information provided herein
pursuant to the Securities Markets Act. The information was sent for publication
on Thursday 22 September 2016, 18:10 (CEST).

Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm,
Sweden (ticker: NUE.ST). Västra Hamnen Corporate Finance AB acts as Certified
Adviser to Nuevolution AB (publ). More information about Nuevolution can be
found on: www.nuevolution.com